{"DataElement":{"publicId":"6819581","version":"1","preferredName":"Positron Emission Tomography Tracer Type","preferredDefinition":"Text term that represents the kind of tracer used in Positron Emission Tomography (PET) imaging.","longName":"6819345v1.0:6819501v1.0","context":"OCG","contextVersion":"1","DataElementConcept":{"publicId":"6819345","version":"1","preferredName":"Positron Emission Tomography Tracer","preferredDefinition":"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered._A substance that is identifiable by virtue of its radioactive signature, color, or other distinguishing physical property, such as a dye, radioactive isotope, or inert chemical, that is introduced into a biological or mechanical system and can be followed through the course of a process, providing information on the pattern of events in the process or on the redistribution of the parts, elements, or events involved.","longName":"2230940v1.0:2519298v1.0","context":"OCG","contextVersion":"1","ObjectClass":{"publicId":"2230940","version":"1","preferredName":"Positron Emission Tomography","preferredDefinition":"A noninvasive imaging method that provides information about cellular activity (metabolic information).  It is used along with magnetic resonance imaging (MRI) which provides information about the shape and size of the tumor (spatial information).","longName":"C17007","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Positron Emission Tomography","conceptCode":"C17007","definition":"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7C5DB4E-AC57-18B5-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-24","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-05-24","modifiedBy":"ONEDATA","dateModified":"2005-05-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2519298","version":"1","preferredName":"Tracer","preferredDefinition":"A substance that is identifiable by virtue of its radioactive signature, color, or other distinguishing physical property, such as a dye, radioactive isotope, or inert chemical, that is introduced into a biological or mechanical system and can be followed","longName":"C2480","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tracer","conceptCode":"C2480","definition":"A substance that is identifiable by virtue of its radioactive signature, color, or other distinguishing physical property, such as a dye, radioactive isotope, or inert chemical, that is introduced into a biological or mechanical system and can be followed through the course of a process, providing information on the pattern of events in the process or on the redistribution of the parts, elements, or events involved.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1D56CF55-D47F-2BA3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-13","endDate":null,"createdBy":"UMLLOADER_PROTLIMS","dateCreated":"2006-09-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2233241","version":"1","preferredName":"Medical Imaging","preferredDefinition":"Events, people, materials and activities uniquely defined by medical imaging.  ","longName":"MEDICAL IMAGING","context":"CIP","contextVersion":"2.31","origin":"DICOM:Digital Imaging and Communications in Medicine","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F96173D7-A9B4-3CBB-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-12","modifiedBy":"SBREXT","dateModified":"2006-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"HCMI:Human Cancer Models Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DCE86A6-AB96-197C-E053-F662850A75B6","latestVersionIndicator":"Yes","beginDate":"2019-07-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-16","modifiedBy":"COOPERM","dateModified":"2019-07-26","changeDescription":"Created for Prostate Cancer request 7.1.19 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6819501","version":"1","preferredName":"PET Tracer Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities.","longName":"6819501v1.0","context":"OCG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other (specify)","valueDescription":"Specify Other","ValueMeaning":{"publicId":"4888051","version":"1","preferredName":"Specify Other","longName":"4888051","preferredDefinition":"Be specific about something; define clearly.: Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"195A90B1-87F5-D292-E050-BB89AD432B03","latestVersionIndicator":"Yes","beginDate":"2015-06-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-06-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8DE14681-211D-68CF-E053-F662850A0E31","beginDate":"2019-07-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-17","modifiedBy":"ONEDATA","dateModified":"2019-07-17","deletedIndicator":"No"},{"value":"Sodium fluoride","valueDescription":"Fluorine F 18 Sodium Fluoride","ValueMeaning":{"publicId":"6819503","version":"1","preferredName":"Fluorine F 18 Sodium Fluoride","longName":"6819503","preferredDefinition":"A radiopharmaceutical consisting of the sodium salt of fluorine F 18 fluoride with radioisotopic and bone mineralizing activities. Fluoride binds to calcium ions in hydroxyapatite crystals in bone. The uptake and incorporation of positron-emitting fluorine F 18 fluoride into bone can be imaged using positron emission tomography (PET) or single-photon emission computed tomography (SPECT), allowing visualization of malignant bone lesions in which regional blood flow and bone turnover are increased.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluorine F 18 Sodium Fluoride","conceptCode":"C66941","definition":"A radiopharmaceutical consisting of the sodium salt of fluorine F 18 fluoride with radioisotopic and bone mineralizing activities. Fluoride binds to calcium ions in hydroxyapatite crystals in bone. The uptake and incorporation of positron-emitting fluorine F 18 fluoride into bone can be imaged using positron emission tomography (PET) or single-photon emission computed tomography (SPECT), allowing visualization of malignant bone lesions in which regional blood flow and bone turnover are increased.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DE14681-212A-68CF-E053-F662850A0E31","latestVersionIndicator":"Yes","beginDate":"2019-07-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-17","modifiedBy":"ONEDATA","dateModified":"2019-07-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8DE14681-2143-68CF-E053-F662850A0E31","beginDate":"2019-07-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-17","modifiedBy":"ONEDATA","dateModified":"2019-07-17","deletedIndicator":"No"},{"value":"PSMA","valueDescription":"Gallium Ga 68-labeled PSMA-11","ValueMeaning":{"publicId":"6819505","version":"1","preferredName":"Gallium Ga 68-labeled PSMA-11","longName":"6819505","preferredDefinition":"A radioconjugate composed of a human prostate specific membrane antigen (PSMA)-targeting ligand, Glu-urea-Lys(Ahx) (Glu-NH-CO-NH-Lys(Ahx)), conjugated, via the acyclic radiometal chelator N,N'-bis [2-hydroxy-5-(carboxyethyl)benzyl] ethylenediamine-N,N'-diacetic acid (HBED-CC), to the radioisotope gallium Ga 68, with potential use as a tracer for PSMA-expressing tumors during positron emission tomography (PET). Upon intravenous administration of the gallium Ga 68-labeled PSMA-11, the Glu-urea-Lys(Ahx) moiety targets and binds to PSMA-expressing tumor cells. Upon internalization, PSMA-expressing tumor cells can be detected during PET imaging. PSMA, a tumor-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gallium Ga 68 Gozetotide","conceptCode":"C118961","definition":"A radioconjugate composed of a human prostate specific membrane antigen (PSMA)-targeting ligand, Glu-urea-Lys(Ahx) (Glu-NH-CO-NH-Lys(Ahx)), conjugated, via the acyclic radiometal chelator N,N'-bis [2-hydroxy-5-(carboxyethyl)benzyl] ethylenediamine-N,N'-diacetic acid (HBED-CC), to the radioisotope gallium Ga 68, with potential use as a tracer for PSMA-expressing tumors during positron emission tomography (PET). Upon intravenous administration of the gallium Ga 68 gozetotide, the Glu-urea-Lys(Ahx) moiety targets and binds to PSMA-expressing tumor cells. Upon internalization, PSMA-expressing tumor cells can be detected during PET imaging. PSMA, a tumor-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DE14681-2150-68CF-E053-F662850A0E31","latestVersionIndicator":"Yes","beginDate":"2019-07-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-17","modifiedBy":"ONEDATA","dateModified":"2019-07-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8DE14681-2169-68CF-E053-F662850A0E31","beginDate":"2019-07-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-17","modifiedBy":"ONEDATA","dateModified":"2019-07-17","deletedIndicator":"No"},{"value":"Acetate","valueDescription":"Carbon-11 Acetate","ValueMeaning":{"publicId":"6819507","version":"1","preferredName":"Carbon-11 Acetate","longName":"6819507","preferredDefinition":"The acetate salt of the radioisotope carbon-11. Although the mechanism is unclear, carbon-11 acetate preferentially accumulates in tumor tissue, serving as a tracer for imaging tumors with positron emission tomography (PET). (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carbon-11 Acetate","conceptCode":"C38712","definition":"The acetate salt of the radioisotope carbon-11. Although the mechanism is unclear, carbon-11 acetate preferentially accumulates in tumor tissue, serving as a tracer for imaging tumors with positron emission tomography (PET). (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DE14681-2176-68CF-E053-F662850A0E31","latestVersionIndicator":"Yes","beginDate":"2019-07-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-17","modifiedBy":"ONEDATA","dateModified":"2019-07-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8DE14681-218F-68CF-E053-F662850A0E31","beginDate":"2019-07-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-17","modifiedBy":"ONEDATA","dateModified":"2019-07-17","deletedIndicator":"No"},{"value":"Choline","valueDescription":"Carbon C 11 Choline","ValueMeaning":{"publicId":"6819509","version":"1","preferredName":"Carbon C 11 Choline","longName":"6819509","preferredDefinition":"A radiotracer consisting of choline labeled with the positron-emitting isotope carbon C 11 with potential imaging use. Upon administration, C-11 choline incorporates into tumor cells through an active, carrier-mediated transport mechanism for choline and then is phosphorylated intracellularly by choline kinase, an enzyme frequently upregulated in human tumors, yielding phosphoryl C-11 choline. In turn, phosphoryl C-11 choline is integrated into phospholipids in the cell membrane as part of phosphatidylcholine. As the proliferation of cancer cells is much higher than normal cells, tumor cells exhibit an increased rate of C-11 choline uptake and incorporation, allowing tumor imaging with positron emission tomography (PET).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carbon C 11 Choline","conceptCode":"C78485","definition":"A radiotracer consisting of choline labeled with the positron-emitting isotope carbon C 11 with potential imaging use. Upon administration, C-11 choline incorporates into tumor cells through an active, carrier-mediated transport mechanism for choline and then is phosphorylated intracellularly by choline kinase, an enzyme frequently upregulated in human tumors, yielding phosphoryl C-11 choline. In turn, phosphoryl C-11 choline is integrated into phospholipids in the cell membrane as part of phosphatidylcholine. As the proliferation of cancer cells is much higher than normal cells, tumor cells exhibit an increased rate of C-11 choline uptake and incorporation, allowing tumor imaging with positron emission tomography (PET).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DE14681-219C-68CF-E053-F662850A0E31","latestVersionIndicator":"Yes","beginDate":"2019-07-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-17","modifiedBy":"ONEDATA","dateModified":"2019-07-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8DE14681-21B5-68CF-E053-F662850A0E31","beginDate":"2019-07-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-17","modifiedBy":"ONEDATA","dateModified":"2019-07-17","deletedIndicator":"No"},{"value":"Axumin","valueDescription":"Fluciclovine F18","ValueMeaning":{"publicId":"6819510","version":"1","preferredName":"Fluciclovine F18","longName":"6819510","preferredDefinition":"A radiotracer containing a synthetic amino acid analogue of L-leucine radiolabeled with fluorine F 18 with potential diagnostic imaging use. Similar to most amino acids, fluciclovine F18 appears to enter cells through the energy-independent L-type amino acid transporter (LAT) system. As an amino acid analogue, this agent is preferentially accumulated by tumor cells due to their increased metabolic needs; however, unlike naturally occurring amino acids, this non-natural amino acid-analogue radiotracer is not metabolized. Accordingly, fluciclovine F18 accumulates in tumor cells and can potentially be used to image tumors using positron emission tomography (PET).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluciclovine F18","conceptCode":"C74002","definition":"A radiotracer containing a synthetic amino acid analogue of L-leucine radiolabeled with fluorine F 18 with potential diagnostic imaging use. Similar to most amino acids, fluciclovine F18 appears to enter cells through the energy-independent L-type amino acid transporter (LAT) system. As an amino acid analogue, this agent is preferentially accumulated by tumor cells due to their increased metabolic needs; however, unlike naturally occurring amino acids, this non-natural amino acid-analogue radiotracer is not metabolized. Accordingly, fluciclovine F18 accumulates in tumor cells and can potentially be used to image tumors using positron emission tomography (PET).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DE14681-21C1-68CF-E053-F662850A0E31","latestVersionIndicator":"Yes","beginDate":"2019-07-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-17","modifiedBy":"ONEDATA","dateModified":"2019-07-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8DE14681-21DA-68CF-E053-F662850A0E31","beginDate":"2019-07-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-17","modifiedBy":"ONEDATA","dateModified":"2019-07-17","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2233241","version":"1","preferredName":"Medical Imaging","preferredDefinition":"Events, people, materials and activities uniquely defined by medical imaging.  ","longName":"MEDICAL IMAGING","context":"CIP","contextVersion":"2.31","origin":"DICOM:Digital Imaging and Communications in Medicine","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F96173D7-A9B4-3CBB-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-12","modifiedBy":"SBREXT","dateModified":"2006-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"HCMI:Human Cancer Models Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DE14681-2105-68CF-E053-F662850A0E31","latestVersionIndicator":"Yes","beginDate":"2019-07-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-17","modifiedBy":"COOPERM","dateModified":"2019-07-26","changeDescription":"Created for Prostate Cancer request 7.17.19 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5806857","version":"1","longName":"HCMI (Human Cancer Models Initiative)","context":"OCG","ClassificationSchemeItems":[{"publicId":"10000016","version":"1","longName":"Prostate","context":"OCG"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"For PET scans, indicate the t","type":"Preferred Question Text","description":"For PET scans, indicate the tracer used","url":null,"context":"OCG"}],"origin":"HCMI:Human Cancer Models Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DE2E8DC-2734-0AD7-E053-F662850AF28D","latestVersionIndicator":"Yes","beginDate":"2019-07-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-17","modifiedBy":"COOPERM","dateModified":"2019-07-26","changeDescription":"Created for prostate request 7.1.19 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}